Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Rating of “Buy” from Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned an average recommendation of “Buy” from the ten research firms that are currently covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $24.44.

Several equities research analysts have weighed in on TEVA shares. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price for the company. Hsbc Global Res raised Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Bank of America lifted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $17.50 on Thursday. The stock has a market capitalization of $20.07 billion, a P/E ratio of -12.07, a PEG ratio of 1.44 and a beta of 0.60. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $22.80. The stock has a 50-day moving average price of $16.12 and a 200-day moving average price of $17.43. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. During the same period in the prior year, the business posted $0.48 EPS. Teva Pharmaceutical Industries’s quarterly revenue was up 1.9% compared to the same quarter last year. Equities analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Matthew Shields sold 6,206 shares of the business’s stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president now directly owns 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.49% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its stake in shares of Teva Pharmaceutical Industries by 0.8% during the first quarter. Rhumbline Advisers now owns 281,062 shares of the company’s stock valued at $4,320,000 after buying an additional 2,128 shares during the last quarter. Strs Ohio bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $2,354,000. Geneos Wealth Management Inc. grew its stake in shares of Teva Pharmaceutical Industries by 49.4% during the first quarter. Geneos Wealth Management Inc. now owns 34,547 shares of the company’s stock valued at $531,000 after buying an additional 11,425 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 43.6% during the first quarter. Intech Investment Management LLC now owns 349,340 shares of the company’s stock valued at $5,369,000 after buying an additional 106,108 shares during the last quarter. Finally, Focus Partners Wealth grew its stake in shares of Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.